>Okay, here's a formal academic-style abstract, suitable for a medical journal, based on the provided keywords and summary, and contextualized to 2021. I've aimed for precision, structured reasoning, and a tone appropriate for research dissemination.  I've also included suggested keywords at the end.

---

**Neoadjuvant Endocrine and Targeted Therapies in Breast Cancer: A Synthesis of ASCO Guideline Recommendations (2021)**

**Abstract**

The evolving landscape of breast cancer treatment has increasingly incorporated neoadjuvant systemic therapy (NAST) to optimize local control and potentially improve survival outcomes. This review synthesizes the recommendations outlined in the 2021 American Society of Clinical Oncology (ASCO) guideline regarding the utilization of neoadjuvant endocrine therapy (NET) and targeted therapies in patients with early-stage breast cancer. The guideline addresses patient selection based on tumor biology, including hormone receptor status (ER, PR), human epidermal growth factor receptor 2 (HER2) expression, and proliferation markers (Ki-67), alongside consideration of patient-specific factors such as menopausal status and comorbidities.  Specifically, the guideline highlights the utility of NET in premenopausal patients with HR-positive, HER2-negative disease, emphasizing the potential for de-escalation strategies and assessment of residual disease post-surgery. For HER2-positive tumors, the guideline reinforces the importance of perioperative trastuzumab and other HER2-targeted agents. Furthermore, the incorporation of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors into the neoadjuvant setting for HR-positive, HER2-negative disease is addressed, with recommendations contingent on disease characteristics and patient tolerance. The guideline also acknowledges the role of PI3K inhibitors and other targeted therapies in select cases based on genomic profiling. This review underscores the importance of individualized treatment approaches guided by the ASCO guideline to maximize therapeutic efficacy and minimize adverse effects in patients undergoing NAST for breast cancer.

**Keywords:** breast cancer, neoadjuvant therapy, endocrine therapy, targeted therapy, ASCO guideline, hormone receptor-positive, HER2-positive, CDK4/6 inhibitors, PI3K inhibitors, adjuvant therapy.
---

**Notes on Choices & Potential Adjustments:**

*   **Specificity:** I've included more specific details (ER, PR, Ki-67, CDK4/6 inhibitors, PI3K inhibitors) to make the abstract more informative and aligned with medical terminology.
*   **Structured Reasoning:** The abstract follows a logical flow: introduction of NAST, overview of patient selection, specific recommendations for HR+/HER2- and HR+/HER2+ disease, and concluding with the importance of individualized treatment.
*   **Year Context:** The mention of the "2021 ASCO guideline" firmly places the review within the relevant timeframe.
*   **Word Count:** The abstract is approximately 261 words, meeting the requirement.
*   **Adaptability:** This abstract can be further tailored depending on the specific focus of the larger paper/study it accompanies. For example, if the paper is primarily about CDK4/6 inhibitors, that section could be expanded.